Related Experiment Video
Updated: Jan 8, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Left atrial-ventricular coupling index associated with new-onset atrial fibrillation in ST-segment elevation
Jiahua Liu1, Xinjia Du1, Jingfang Zhou1
1Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Insights
The Left Atrial-Ventricular Coupling Index (LACI) is independently associated with new-onset atrial fibrillation (NOAF) in ST-segment elevation myocardial infarction (STEMI) patients. Incorporating LACI improves the identification of patients at higher risk for NOAF after PCI.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Electrophysiology
Background:
- Management of new-onset atrial fibrillation (NOAF) in ST-segment elevation myocardial infarction (STEMI) patients presents clinical challenges.
- The Left Atrial-Ventricular Coupling Index (LACI) is an emerging cardiovascular risk marker.
- The association between LACI and NOAF in STEMI patients is not well-established.
Purpose of the Study:
- To investigate the relationship between LACI, measured by cardiac magnetic resonance (CMR), and the occurrence of NOAF post-percutaneous coronary intervention (PCI) in STEMI patients.
Main Methods:
- A retrospective, single-center study enrolled STEMI patients from September 2018 to December 2024 who underwent CMR.
- LACI was calculated as the ratio of left atrial end-diastolic volume index to left ventricular end-diastolic volume index.
- Multivariable logistic regression and ROC curve analyses were performed.
Main Results:
- Of 553 STEMI patients, 46 developed NOAF.
- LACI (OR=1.10), microvascular obstruction (OR=1.16), and heart rate (OR=1.03) were independent risk factors for NOAF.
- LACI demonstrated good predictive performance (AUC=0.733) and significantly improved NOAF risk prediction models.
Conclusions:
- LACI is an independent predictor of NOAF following PCI in STEMI patients.
- Integrating LACI into risk assessment models enhances the identification of patients at elevated risk for NOAF.
Background:
The management of new-onset atrial fibrillation (NOAF) in ST-segment elevation myocardial infarction (STEMI) patients remains a challenge in clinical. Left atrial-ventricular coupling index (LACI) is a novel cardiovascular risk marker. Currently, the relationship between LACI and NOAF in STEMI patients is unclear. This study aims to investigate the association between LACI measured by cardiac magnetic resonance (CMR) and NOAF after PCI in STEMI patients.
Methods:
This is a single-center, retrospective study. Patients who were admitted for STEMI from September 2018 and December 2024 were consecutively enrolled. All patients completed CMR during hospitalization. LACI was calculated as the ratio of the left atrial end-diastolic volume index to the left ventricular end-diastolic volume index.
Results:
A total of 553 patients were included, of whom 46 developed NOAF. Multivariable logistic regression analysis indicated that LACI (OR = 1.10, 95% CI: 1.07-1.14, p < 0.001), microvascular obstruction (OR = 1.16, 95% CI: 1.07-1.26, p < 0.001), and heart rate (OR = 1.03, 95% CI: 1.01-1.06, p = 0.024) were independent risk factors for NOAF. Receiver operating characteristic (ROC) curve analysis showed that the AUC for LACI was 0.733 (95% CI: 0.636-0.830, p < 0.001). Integrating LACI significantly improved the NOAF risk model (NRI = 0.803, 95% CI: 0.5149-1.0917, P < 0.001; IDI = 0.127, 95% CI: 0.0606-0.1930, P < 0.001).
Conclusion:
LACI is independently associated with the occurrence of NOAF after PCI in patients with STEMI. Incorporating LACI into the analytical model improves its ability to identify patients with higher NOAF risk.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome I: Introduction
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Mitral Regurgitation II: Clinical Features and Diagnostic Tests

